Biomissile

Executive Summary

Biomissile is a private Chinese biotech company founded in 2020, headquartered in Suzhou, specializing in the discovery and development of multi-specific therapeutic antibodies. The company leverages its proprietary fully human domain antibody (UDAB™) platform to create innovative biologics, primarily bispecific and multispecific antibodies, targeting diseases with significant unmet medical needs in oncology and immunology. With a pipeline of over 10 preclinical candidates, Biomissile aims to address treatment gaps where effective therapies are lacking. The company operates at the preclinical stage, with no disclosed funding or valuation, but its platform technology positions it as a potential player in the rapidly growing multi-specific antibody space. Given the early stage, key risks include technical validation, regulatory hurdles, and competition from larger biotech firms. However, the UDAB™ platform's ability to generate fully human antibodies may offer advantages in immunogenicity and developability.

Upcoming Catalysts (preview)

• Q3 2026Lead candidate IND filing (e.g., anti-PD-L1/TGFβ bispecific)50% success
• Q4 2026Preclinical data presentation at major conference (e.g., SITC 2026)70% success
• Q2 2027Partnership or licensing deal for UDAB™ platform30% success